Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FDD85
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $7,737
Award facts
- Contract value 100% obligated
- $7,737.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,737 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The contract was executed on October 29, 2025, with an ultimate completion date of November 20, 2025, under firm fixed-price terms with no set-aside designation. This delivery order was issued against DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors for the Department of Defense's pharmaceutical supply needs worldwide.
The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, carries a ceiling value of $499.999 billion and extends through December 31, 2036, encompassing a 30-month base period and three 30-month option periods. As a critical pharmaceutical supplier within the federal military medical supply chain, DMS Pharmaceutical Group distributes a comprehensive portfolio including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals to support Department of Defense healthcare operations globally. The company's established performance on numerous prior delivery orders demonstrates its capability to fulfill the diverse and specialized pharmaceutical requirements of military medical facilities worldwide.
Quick answers
Who was awarded contract SPE2DB26FDD85?
SPE2DB26FDD85 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DB26FDD85 worth?
The government has obligated $7,737 on SPE2DB26FDD85.
Is contract SPE2DB26FDD85 an order under another contract?
Yes. SPE2DB26FDD85 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB26FDD85 competed?
The extent of competition for SPE2DB26FDD85 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award